3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Active not recruiting
7
Recruiting
5
Terminated
3
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Cancer Female
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Radiosurgery
7
Oxaliplatin
7
Docetaxel
7
Paclitaxel
5
Fluorouracil
5
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Carboplatin
4
Capecitabine
4
Trastuzumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
spartalizumab
2
sipuleucel-T
2
repotrectinib
2
pembrolizumab
2
pazopanib
2
orteronel
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Temozolomide
2
Surveys and Questionnaires
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm Metastasis
×
durvalumab
×
Clear all
NCT04184518
2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2
Withdrawn